-
公开(公告)号:US07786139B2
公开(公告)日:2010-08-31
申请号:US12124051
申请日:2008-05-20
申请人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
发明人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
IPC分类号: A01N43/42 , A61K31/47 , C07D215/00
CPC分类号: A61K31/341 , A61K31/404 , A61K31/4184 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/5415 , C07D209/18 , C07D213/81 , C07D215/36 , C07D235/16 , C07D235/28 , C07D249/18 , C07D279/16 , C07D333/24 , C07D405/12
摘要: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
摘要翻译: 公开了抑制PDE10的化合物,其可用于治疗各种病症,包括(但不限于)精神病性,焦虑症,运动障碍和/或神经障碍,例如帕金森病,亨廷顿氏病,阿尔茨海默病,脑炎,恐惧症 癫痫,失语症,贝尔麻痹,脑性麻痹,睡眠障碍,疼痛,图雷特综合征,精神分裂症,妄想症,药物诱发的精神病,恐慌和强迫症。 该化合物具有以下通式:其中m,n,p,x,R,R 1,R 2,R 3,R 4,R 5,A和B在本文中定义,包括其药学上可接受的盐,立体异构体,溶剂合物或前药。 还公开了含有本发明化合物与药学上可接受的载体的组合物的组合物,以及涉及其在需要其的温血动物中用于抑制PDE10的方法。
-
公开(公告)号:US08278327B2
公开(公告)日:2012-10-02
申请号:US12848766
申请日:2010-08-02
申请人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
发明人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
IPC分类号: A01N43/42 , A61K31/47 , C07D215/00
CPC分类号: A61K31/341 , A61K31/404 , A61K31/4184 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/5415 , C07D209/18 , C07D213/81 , C07D215/36 , C07D235/16 , C07D235/28 , C07D249/18 , C07D279/16 , C07D333/24 , C07D405/12
摘要: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
摘要翻译: 公开了抑制PDE10的化合物,其可用于治疗各种病症,包括(但不限于)精神病性,焦虑症,运动障碍和/或神经障碍,例如帕金森病,亨廷顿氏病,阿尔茨海默病,脑炎,恐惧症 癫痫,失语症,贝尔麻痹,脑性麻痹,睡眠障碍,疼痛,图雷特综合征,精神分裂症,妄想症,药物诱发的精神病,恐慌和强迫症。 该化合物具有以下通式:其中m,n,p,x,R,R 1,R 2,R 3,R 4,R 5,A和B在本文中定义,包括其药学上可接受的盐,立体异构体,溶剂合物或前药。 还公开了含有本发明化合物与药学上可接受的载体的组合物的组合物,以及涉及其在需要其的温血动物中用于抑制PDE10的方法。
-
公开(公告)号:US20110021509A1
公开(公告)日:2011-01-27
申请号:US12848766
申请日:2010-08-02
申请人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
发明人: John E. Bergmann , Neil S. Cutshall , Rene Onrust , Hongkui Zeng , Jennifer Lynn Gage , Derek Johnston , Sándor Cseh , László Ürögdi , Ákos Papp
IPC分类号: A61K31/5415
CPC分类号: A61K31/341 , A61K31/404 , A61K31/4184 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/5415 , C07D209/18 , C07D213/81 , C07D215/36 , C07D235/16 , C07D235/28 , C07D249/18 , C07D279/16 , C07D333/24 , C07D405/12
摘要: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
摘要翻译: 公开了抑制PDE10的化合物,其可用于治疗各种病症,包括(但不限于)精神病性,焦虑症,运动障碍和/或神经障碍,例如帕金森病,亨廷顿氏病,阿尔茨海默病,脑炎,恐惧症 癫痫,失语症,贝尔麻痹,脑性麻痹,睡眠障碍,疼痛,图雷特综合征,精神分裂症,妄想症,药物诱发的精神病,恐慌和强迫症。 该化合物具有以下通式:其中m,n,p,x,R,R 1,R 2,R 3,R 4,R 5,A和B在本文中定义,包括其药学上可接受的盐,立体异构体,溶剂合物或前药。 还公开了含有本发明化合物与药学上可接受的载体的组合物的组合物,以及涉及其在需要其的温血动物中用于抑制PDE10的方法。
-
-